drugset / Trial / NCT02222324

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

NCT02222324

Phase 1 Completed 60 enrolled Eisai Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

This thorough QT (TQT) study will take place in healthy subjects administered single doses of study drug. It will be a randomized, double-blind, placebo and active-controlled, 4-treatment crossover study. Subjects will be randomized in an equal ratio to one of 12 possible treatment sequences. Each treatment sequence will comprise all 4 treatments.

Timeline

Start
2014-08
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Elenbecestat Small molecule
Comparator Moxifloxacin Small molecule

Indications

No indication recorded.